A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now Nathan C Lo, David G Addiss, Peter J Hotez, Charles H King, J Russell Stothard, Darin S Evans, Daniel G Colley, William Lin, Jean T Coulibaly, Amaya L Bustinduy, Giovanna Raso, Eran Bendavid, Isaac I Bogoch, Alan Fenwick, Lorenzo Savioli, David Molyneux, Jürg Utzinger, Jason R Andrews In 2001, the World Health Assembly (WHA) passed the landmark WHA 54.19 resolution for global scale-up of mass administration of anthelmintic drugs for morbidity control of schistosomiasis and soil-transmitted helminthiasis, which affect more than 1·5 billion of the world's poorest people. Since then, more than a decade of research and experience has yielded crucial knowledge on the control and elimination of these helminthiases. However, the global strategy has remained largely unchanged since the original 2001 WHA resolution and associated WHO guidelines on preventive chemotherapy. In this Personal View, we highlight recent advances that, taken together, support a call to revise the global strategy and guidelines for preventive chemotherapy and complementary interventions against schistosomiasis and soiltransmitted helminthiasis. These advances include the development of guidance that is specific to goals of morbidity control and elimination of transmission. We quantify the result of forgoing this opportunity by computing the yearly disease burden, mortality, and lost economic productivity associated with maintaining the status quo. Without change, we estimate that the population of sub-Saharan Africa will probably lose 2·3 million disability-adjusted life-years and US$3·5 billion of economic productivity every year, which is comparable to recent acute epidemics, including the 2014 Ebola and 2015 Zika epidemics. We propose that the time is now to strengthen the global strategy to address the substantial disease burden of schistosomiasis and soil-transmitted helminthiasis.
Introduction
More than 15 years ago, the World Health Assembly (WHA) passed the landmark WHA 54.19 resolution to address the 1·5 billion people affected by schistosomiasis and soil-transmitted helminthiasis (including ascariasis, hookworm disease, and trichuriasis).
1,2
WHO subsequently created a Department of Neglected Tropical Diseases (NTDs), and produced guidelines that set a new framework for a public health approach against many NTDs, including schistosomiasis and soil-transmitted helminthiasis, through a strategy of preventive chemotherapy (via mass drug admin istration). 3 This strategy involves large-scale, periodic (eg, yearly) empirical treatment of entire populations and typically focuses on groups assumed to have the greatest disease morbidity, such as school-aged children (aged 5-15 years) for schistosomiasis and preschool and school-aged children (aged 1-15 years) for soil-transmitted helminthiasis. 3, 4 These helminthiases are characterised by mostly chronic, often insidious helminth-specific sequelae ranging from mild to severe morbidities. These sequelae include anaemia, chronic abdominal pain, and malnutrition, and also more rare and serious complications including bladder cancer, hepato splenomegaly, and death for schistosomiasis, and small bowel obstruction and rectal prolapse for soil-transmitted helminthiasis.
Today, under the auspices of the WHO Department of NTDs-catalysed by the 2012 London Declaration for NTDs, and with large-scale support from governments, pharmaceutical companies, and non-governmental organisations (NGOs)-preventive chemotherapy programmes have achieved impressive gains. In 2015 alone, these programmes delivered treatment to 65 million people using praziquantel (against schistosomiasis) and 565 million people using albendazole or mebendazole (against soil-transmitted helminthiasis) throughout Africa, Asia, Latin America, and the Middle East. 5, 6 During this period, the number of infections and global disease burden estimates have been correspondingly reduced.
1,2,7 This strategy of morbidity control has defined a goal of eliminating helminths as a public health problem. For soiltransmitted helminthiasis, this goal is defined as less than 1% prevalence of moderate-to-heavy intensity infection in at-risk populations, as determined by egg counts on microscopic examination; for schistosomiasis, the goal has been expressed as less than 1% prevalence of heavyintensity infections based on egg counts in stools or urine.
Although this commendable morbidity control strategy has certainly led to success, mainly by averting long-term sequelae in school-aged children, the reinfection rate has been high in most settings. 8, 9 Unfortunately, even countries that have successfully implemented the recommended preventive chemotherapy strategy for schistosomiasis and soil-transmitted helminthiasis-ie, WHO recommends repeated treatment of school-aged children with at least 75% coverage-have met challenges in achieving optimal morbidity control or the more ambitious goal of transmission elimination. 8, 10, 11 This finding is consistent with estimates by the Global Burden of Disease (GBD) study 12 and others 5 that have documented how progress has lagged behind for schistosomiasis and soiltransmitted helminthiasis relative to many other NTDs. To address this challenge, in light of the past decade of data and experience from the field, we re-visit the global strategy for preventive chemotherapy and complementary interventions against schistosomiasis and soil-transmitted helminthiasis.
Preventive chemotherapy
As the post-2020 agenda for NTDs is considered, interest is growing in improving the morbidity control strategy, and when appropriate, shifting towards a more ambitious goal of elimination of transmission, which is defined as interruption of transmission. The critical, policyrelevant question to be asked is how we can use new evidence to strengthen current strategies and guidelines for preventive chemotherapy to achieve these goals (table 1). The current strategy of morbidity control emphasises treatment of school-aged children alone (with extension to preschool-aged children for soiltransmitted helminthiasis); however, adolescents and adults (15 years and older, including pregnant women) and younger children (<5 years) in the case of schistosomiasis, are often infected and are not sufficiently addressed in exisiting global strategy or in parasitological monitoring. 3, 4, 31 If left untreated, these groups can serve as a hidden reservoir and potential source of reinfection for all age groups. Modelling studies indicate that expanding treatment from school-aged children alone to entire communities could substantially reduce reinfection across all age groups, and avert accumulated morbidity in these populations, especially schistosomiasis-related chronic sequelae in preschoolaged children. 10, 13, 29, 31, 32 The relative advantage of community-based treatment has been further supported by a systematic review and meta-analysis of observational studies. 16 Furthermore, expanded community-wide treatment can be highly cost-effective because of this averted morbidity, even if transmission is not eliminated. 10, 14 To achieve community-wide coverage, settings could use distribution networks from other community-based health platforms for feasibility and cost-efficiency, including integration with vaccination programmes, Demographic and Health Surveys (DHS), or through continued use of lymphatic filariasis or onchocerciasis drug distributors who have delivered community-wide anthelmintics (eg, ivermectin and albendazole) at scale. 33, 34 Guidelines currently provide prevalence thresholds, above which a preventive chemotherapy strategy is recommended, but these guidelines might be too restrictive to achieve optimal averted disability and costeffectiveness even under a goal of morbidity control.
14 These prevalence thresholds are based on expert opinion and a historically more limited drug supply, and have remained largely unchanged for more than a decade.
3,4
Although these thresholds have guided efforts in preventive chemotherapy, analysis of new data suggests they can be improved by considering transmission dynamics and health economics. 10, 14 A study that rigorously assessed these prevalence thresholds found them to often be too restrictive on the basis of morbidity control (measured in disability-adjusted life-years [DALYs]) and cost-effectiveness, especially for schistosomiasis.
14 For example, annual school-based treatment of schistosomiasis was cost-effective at 5% prevalence rather than the currently recommended 50% prevalence, and new prevalence thresholds were defined for community-wide coverage for both sets of helminthiases. 14 Although expanded treatment would have great potential to avert disease morbidity, reduce overall reinfection, and prevent chronic sequelae in young children, the potential emergence of drug resistance from increased treatment pressure is a concern. Therefore, rigorous methods to monitor drug efficacy will be essential, although community-wide treatment at 75% coverage still falls under the best practices according to conservative estimates from veterinary literature. 35 This concern can further be addressed by a longer-term but necessary research and development agenda to create improved drug regimens with greater efficacies against schistosomiasis and soil-transmitted helminthiasis (particularly trichuriasis), for which drug efficacy might be lower than expected, or even anthelmintic vaccines to prevent reinfection. [36] [37] [38] New diagnostics for helminths (eg, point-of-care circulating cathodic antigen urine cassette test for Schistosoma mansoni) can also be applied to guide new treatment thresholds. 39 Re-examination of the preventive chemotherapy strategy should also consider evidence from the Cochrane Collaboration 40 and Campbell Collaboration 41 systematic reviews and meta-analyses of trial data that suggest limited benefit of school-based preventive chemotherapy
Strength of evidence
Step 1: Update strategy for preventive chemotherapy Expanded treatment across broader age groups (ie, community-wide treatment)
Modelling and cost-effectiveness studies, 10, [13] [14] [15] with support from systematic review and meta-analysis of observational studies 16 Lower prevalence thresholds for treatment, especially for schistosomiasis Modelling and cost-effectiveness studies, 14 with support from observational studies Formal guidelines for integration of praziquantel and benzimidazole programming Cost-effectiveness modelling studies, with support from feasibility studies 10, 14, 17, 18 Validated strategy with trial data Trials underway
Rigorous monitoring and evaluation strategies to detect emergence of drug resistance
Statistical models with field validation 19
Step 2: Incorporate complementary interventions in the global strategy
Water, sanitation, and hygiene programming (eg, community-led total sanitation) Systematic review and meta-analysis with mixed findings, including mostly observational studies [20] [21] [22] [23] [24] [25] [26] [27] [28] Information, education, and communication programmes
Trial data 26 Snail control (for Schistosoma spp) Systematic review and meta-analysis, including mostly observational studies; modelling studies 29, 30 Step 3: Create distinct guidelines based on epidemiology, programmatic goals, and resource constraints
Guidelines for a goal of morbidity control vs elimination of transmission Expert opinion [42] [43] [44] For example, studies might be under powered to detect a meaningful effect and relevant health outcomes might not be realised within the short timeframe of most trials. Furthermore, children could have high rates of reinfection in schoolbased programmes that limit improvements to health, but this could be overcome with community-wide treatment strategies. 10, 16, 32 The updated global strategy for preventive chemotherapy should increase attention to country-level coordination of integrated programmatic delivery (ie, giving multiple medicines in the same programme) that would yield substantial cost-savings and biological synergies within the constraints of proven feasibility. 10, 14, 17, 18 Although integrated preventive chemotherapy guidelines do exist, improving country-level coordination of these programmes would benefit cost-efficiency.
14, 45 The prevalence threshold itself is lower for adding another medicine in addition to an existing treatment programme compared with a standalone programme due to reduced delivery cost, and because the majority of cost is from delivery and not the drugs themselves. 10, 17 For example, programmatic delivery of praziquantel should include albendazole or meben dazole, as done by the Schistosomiasis Control Initiative, because soiltransmitted helminthiasis is most often co-endemic and co-administration is safe. 18 The integration of these programmes should work within the constraints of the drug supply and the relevant ecological zone (eg, national, sub-national, community) to address the focal nature of schistosomiasis, which is in contrast with the more homogeneous nature of soil-transmitted helminthiasis.
Complementary interventions
The global strategy should include water, sanitation, and hygiene (WASH) interventions, information, education, and communication (IEC) programmes, and focal snail control (for schistosomiasis), especially when elimination of transmission is the goal. Coordinated guidelines are needed that define the conditions (eg, prevalence threshold, programmatic goals) where each complementary intervention should be implemented alongside preventive chemotherapy within the broad framework of local health needs. While WASH programming, IEC, and snail control are not the focus of current global efforts, growing evidence supports the need for greater inclusion within the updated strategy, especially where disease dynamics are recalcitrant to preventive chemotherapy alone or elimination of transmission is the goal.
Implementation of the WHO WASH-NTD global strategy will probably be essential to eliminate transmission. 20 Observational studies have provided evidence for the association between various components of WASH (including improved water, sanitation, and hygiene and health behaviour) and helminth prevalence and mean intensity. [21] [22] [23] [24] [25] However, experimental evidence from trials implementing WASH interventions is mixed, and studies are ongoing to validate the data from observational studies. 23, [25] [26] [27] [28] Nonetheless, these programmes are likely to have substantial spillover benefit by reducing the incidence of other infectious diseases improving country-level cost-effectiveness. 25 The importance of snail control in schistosomiasis control and elimination has been supported by a metaanalysis, 29 empirical analyses of historical data, 30 and modelling studies. 46 The inclusion of multiple means of snail control within a coordinated strategy alongside preventive chemotherapy for schistosomiasis is an important step forward to eliminate transmission in low endemicity settings and also to control disease morbidity in high endemicity settings.
Guidelines for morbidity control versus elimination of transmission
Distinct programmatic guidance is urgently needed that is specific to the different goals of morbidity control or elimination of transmission, and is informed by the setting's local helminthiases epidemiology and health priorities of the country. Decisions about strategy should further be made on a sub-national basis with consideration of the focal nature of schistosomiasis. Disease burden differs considerably among settings, and elimination of transmission might not be possible in all locations with existing tools and resources. High-burden settings could set a near-term goal of morbidity control, while low-burden settings could target elimination of transmission. In all cases, settings should first aim to achieve effective morbidity control before expanding to a goal of elimination of transmission.
To achieve these goals, settings targeting the goal of morbidity control should focus on ensuring high drug coverage in all risk groups, including preschool-aged children and adults. By contrast, settings with low prevalence might set a goal of eliminating transmission and could prioritise non-drug interventions such as WASH programming, snail control, and intensive surveillance. 47 In all cases, the country's goals and resource constraints will inform this choice, and distinct strategic recommendations should be available to reflect these different scenarios. Programmatic goals should be established with full country ownership of these programmes, especially in regions with an improving economy and health systems. In developed countries, particular attention should be given to "blue marble health", which recognises that the sizable proportion of the global burden of helminthiasis that occurs in the poorer populations of wealthy countries will require distinct strategies and political support structures. 48 See Online for appendix
Personal View
The proposed revision to the global strategy could substantially expand the target population for preventive chemotherapy and resources needed for complementary interventions. In countries that have yet to achieve the 2020 goal of at least 75% drug coverage of all at-risk populations, development of an updated strategy will serve to clarify resource, drug supply, and programmatic needs to attain the 2020 goal and beyond. In settings that have reached 75% drug coverage targets, strengthened guidance should provide an evidence-based strategy towards a post-2020 era through a more ambitious and well defined goal of optimal morbidity control or elimination of transmission without allowing for infection rebound.
The historic creation of many aspirational targets in global health, including the 3 by 5 initiative for HIV/ AIDS, the Millennium Development Goals, and the London Declaration on NTDs, illustrates the potential of setting a higher bar to improve human health. The inclusion of NTDs as a specific target within the UN Sustainable Development Goals further signifies the importance of addressing NTDs to achieve universal health coverage. 49 To quantify the potential gains of strengthening the global strategy for schistosomiasis and soil-transmitted helminthiasis, we compared evidence-based strategies for preventive chemotherapy relative to the current global strategy and idealised WHO guidelines. Without change, we estimate that the population of subSaharan Africa will probably lose 2·3 million DALYs and US$3·5 billion of economic productivity every year, which is similar to the impact of recent acute epidemics, including the 2014 Ebola and 2015 Zika epidemics (table 2, appendix).
Conclusions
With a shared goal of reducing the burden of NTDs on the world's poorest people, and following the leadership of WHO Director-General Margaret Chan and colleagues around the world for NTDs, we respectfully advocate for revision of the global strategy and associated WHO 14 relative to each strategy. ‡Estimation based on WHO guidelines with current global coverage for preventive chemotherapy. §Estimation based on WHO guidelines with 75% coverage and uses school-based preventive chemotherapy programmes, except for inclusion of preschool-aged children in soil-transmitted helminthiasis treatment.
Results are annualised over a 5-year simulation and are intended to give a broad estimate of the magnitude of avertable health and economic loss. Methodological details, limitations, and discussions of uncertainty are provided in the appendix. Contributors NCL conceived the article and did the data analysis. NCL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed intellectual material and approved the final draft.
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